Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Jordan ZinbergVitalHub Corp.VHI.VPARTIAL BUYMar 01, 2022

He got in very early at 15 cents. Their software help hospitals manage patients and increase efficiency. Very active in the UK. Management has built a company like this before and are doing it again now. Topline growth has been great, but he'd like to see more profit growth. The stock is a good trader around $3 where it has been stuck. This could be a take-out candidate one day, but nothing is imminent.
$2.98

Stock price when the opinion was issued

$2.98

As of Sep 22, 2021. Market Open.

Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

2Q sales rose 38% to $13.1M; margins dipped to 81% from 83% due to an increase in lower margin service revenue. EBITDA nearly doubled to $1.9M. Net income was $0.72M from a loss last year. Cash was $22M. Results look good to us; Cormark raised its target price slightly. EPS is predicted to double in 2024, with slower growth following the next year. 
Unlock Premium - Try 5i Free

BUY ON WEAKNESS

Healthcare tech company.
Has owned on and off over the past few years.
Very strong management team.
Multiple is high given current share price.
Defensive software name.

Unspecified
It is a patient flow technology company combining health and technology. He has held it off and on in varying amounts over the years. Management has done a great job growing the business and producing recurring revenue. Although it is doing the right things he would like to see more profitability and a higher ROE.
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales growth has restarted. Margins contracted slightly. Revenues increased by 36% from the same quarter a year prior. They overall missed their quarter but growth prospects still look pretty good. Unlock Premium - Try 5i Free

PARTIAL BUY
They are buying small healthcare tech companies. They have been executing the acquisition plan at a pretty good pace. Sometimes it gets lumped in with the more speculative healthcare tech companies. They have a lot of cash on the balance sheet. (Analysts’ price target is $4.77)
RISKY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Competition in the space has increased. The valuation has reached above 6x sales. Valuation is more reasonable at 3x sales. The company also has small cap risk but sales growth has been strong. A 5+ years time horizon. Unlock Premium - Try 5i Free

WATCH
He kind of likes this business. The valuation is more reasonable than some others in the space. He is keeping his eye on it. They are in a good segment of the business.
COMMENT
He spoke with management about 2 weeks ago. 2020 is the year of great opportunity for them. They continue to win large contracts here and in the Middle East. He does not own it. (Analysts’ price target is $3.25)
COMMENT
Something happened to this on Jan. 6 (a 10-2 stock split), and it's up 1,100% this month. Hard to talk about this, technically. Do fundamental analysis. Maybe enter at $2.20. Reverse consolidations are usually not good.
WATCH
Tech analysis on penny stocks is very difficult. We need to get through somewhere we haven't been. Have to prove the stock wants to go higher.
DON'T BUY
It's starting to look toppy. He needs it to rise above its current price range before he'd buy.
BUY
It's tried many times to rise above 20 cents, beyond a spike, and he'd love it to do that. He would gamble on that happening. It's long been steady.